Europe PMC
open access
CC BY 4.0
Tigecycline Combined with Homoharringtonine Synergistically Exerts Anti-Leukemia Effects via AKT/mTOR/4EBP1 Pathway-Mediated Inhibition of Mitochondrial Translation
Abstract Tigecycline (TIG), a derivative of tetracycline antibiotics, has exhibited antitumor activity against a range of solid tumors and hematologic malignancies, with combination regimens often yielding superior inhibition. To develop new TIG-based combinations for myeloid leuk
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia#369856
- A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia#1088508
- Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)#800386
- IA14 Induction in Young Acute Myeloid Leukemia#842909
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)#871866
Record · ID 1175114
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive